Holen Sie sich die Stockscreener-App
137.64
0.66%
-0.91
Handel nachbörslich:
137.88
0.24
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$138.55
Offen:
$138.95
24-Stunden-Volumen:
7.34M
Relative Volume:
1.06
Marktkapitalisierung:
$170.84B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
20.29
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-0.97%
1M Leistung:
-4.68%
6M Leistung:
+12.08%
1J Leistung:
+31.66%
1-Tages-Spanne:
$136.69
$139.76
1-Wochen-Bereich:
$136.69
$141.40
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.64 | 170.84B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
927.03 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.18 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
208.38 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.80 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.07 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by GF Fund Management CO. LTD. - MarketBeat
Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd. - MarketBeat
Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview - Insider Monkey
Jim Cramer on Gilead Sciences: “I’d Hold On to It” - Insider Monkey
Gilead Sciences stock edges lower as research teams attend AACR26 to advance cancer therapies - Traders Union
Gilead (GILD) Extends Tender Offer for Arcellx (ACLX) to April 2 - GuruFocus
Gilead extends Arcellx tender offer again - MSN
Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group - MarketBeat
Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings - Insider Monkey
Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating - Moomoo
Gilead extends Arcellx tender offer again (GILD:NASDAQ) - Seeking Alpha
Gilead Sciences (NASDAQ: ACLX) offers $115 per share plus CVR; deadline extended - Stock Titan
Gilead Sciences patents new GTPase KRAS G12D inhibitors - BioWorld News
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating - Moomoo
Gilead extends Arcellx tender offer to April 27 - Investing.com
Gilead extends Arcellx tender offer to April 27 By Investing.com - Investing.com India
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - Business Wire
Mirae Asset Global Investments Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gene Transplant Market Is Going to Boom | Novartis • Gilead Sciences • Kite Pharma • Bluebird Bio - openPR.com
Farther Finance Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc. - MarketBeat
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $422,880.00 in Stock - MarketBeat
Gilead Sciences CFO Dickinson sells $422k in stock - Investing.com
Gilead Sciences exec Mercier sells $422k in stock - Investing.com
Gilead Sciences (NASDAQ: GILD) CFO sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead (GILD) executive Johanna Mercier sells 3,000 shares under 10b5-1 plan - Stock Titan
Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns - Yahoo Finance
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
RBC Capital maintains Gilead Sciences stock rating on Yeztugo concerns - Investing.com
Gilead to Acquire Tubulis, Strengthing Oncology Pipeline - CHEManager
KBC Group NV Has $398.25 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Lbp Am Sa Has $27.41 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Zacks Research Expects Lower Earnings for Gilead Sciences - MarketBeat
Gilead Sciences (GILD) to Release Quarterly Earnings on Thursday - MarketBeat
TEM Stock Jumps As ARK, Medtronic, Gilead Fuel AI Healthcare Story - timothysykes.com
Insider sales at GILD (NASDAQ: GILD) — 31,000 shares for $4.76M reported - Stock Titan
AIDS Healthcare Foundation calls out Gilead Sciences over the high cost of HIV medications in Florida - WTXL ABC 27 Tallahassee News
Zacks Research Predicts Weaker Earnings for Gilead Sciences - MarketBeat
BofA Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $162 - Moomoo
Bingham Private Wealth LLC Invests $1.42 Million in Gilead Sciences, Inc. $GILD - MarketBeat
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access - BioSpace
Gilead Sciences (GILD) to acquire Tubulis for $5B to strengthen oncology pipeline - MSN
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today - Yahoo Finance
Gilead Sciences Inc. stock rises Tuesday, still underperforms market - MarketWatch
Gilead Sciences stock (US3755581036): Is HIV dominance still enough for long-term investor gains? - AD HOC NEWS
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.00%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):